Devonian Health Group, Inc.

As of April 30, 2026, Devonian Health Group Inc. carries a market capitalization of 29.85M, placing it among publicly traded companies globally. Its enterprise value stands at 29.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of April 30, 2026, Devonian Health Group Inc. has 2.78M shares outstanding.

These figures are as of April 30, 2026. The price-to-sales ratio is 13.11, and the price-to-book ratio stands at 5.81.

These figures are as of April 30, 2026. The EV/Sales ratio of 13.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 29.43M versus a market cap of 29.85M, with the gap driven by net debt and cash on the balance sheet.

As of April 30, 2026, Devonian Health Group Inc. maintains a current ratio of 1.00, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.01, indicating elevated leverage, while an interest coverage ratio of -690.83 demonstrates limited ability to service its debt obligations.

Over the twelve months ended April 30, 2026, Devonian Health Group Inc. posted a negative return on equity (ROE) of -77.33, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -38.71, reflecting losses generated across the asset base. The company generates approximately 200,452.40 in revenue per employee across its workforce of 11.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 35.76 indicates how many times Devonian Health Group Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended April 30, 2026, Devonian Health Group Inc. recorded an income tax benefit of -9,337.39 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -4.51M and -4.50M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 6, 2026, Devonian Health Group Inc.'s stock has gained approximately 15.80% over the past 52 weeks.

Over the twelve months ended April 30, 2026, Devonian Health Group Inc. generated 2.20M in revenue and converted that into -4.50M in net income, yielding earnings per share of -1.67. EBITDA reached -4.41M, while operating income came in at -4.56M.

As of April 30, 2026, Devonian Health Group Inc. holds 529,981.38 in cash and equivalents against 103,461.40 in total debt, resulting in a net debt position of -529,981.38. Total book value stands at 5.14M, with working capital of -3,811.07 providing operational flexibility.

Devonian Health Group Inc. produced -8.66M in operating cash flow over the twelve months ended April 30, 2026. After subtracting -4,785.01 in capital expenditures, free cash flow totaled -8.67M - equivalent to -3.22 per share.

Over the twelve months ended April 30, 2026, Devonian Health Group Inc. posted a gross margin of 67.89, reflecting its pricing power and cost economics. The operating margin of -206.69 and net profit margin of -204.08 provide insight into operational efficiency.

These figures cover the twelve months ended April 30, 2026. Free cash flow yield is negative at -29.99: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -6.74, meaning Devonian Health Group Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Devonian Health Group Inc.'s most recent stock split took place on January 22, 2026 with a 60:1 split ratio.

As of April 30, 2026, Devonian Health Group Inc. has an Altman Z-Score of -4.59, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.